Recombinant multi-species LGALS3BP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LGALS3BP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 90K,BTBD17B,Basement membrane autoantigen p105,CyCAP,Galectin-3-binding protein,LGALS3BP,Lectin galactoside-binding soluble 3-binding protein,Lgals3bp,M2BP,MAC-2-BP,MAC-2BP,MAC2BP,Mac-2 BP),Mac-2-binding protein (MAC2BP,Ppicap,TANGO10B,Tango10b,Tumor-associated antigen 90K,gp90,mama

Target products collectionGo to LGALS3BP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IO086-Ag-1/ GM-Tg-hg-IO086-Ag-2 Human LGALS3BP protein Human
GM-Tg-rg-IO086-Ag-1/ GM-Tg-rg-IO086-Ag-2 Rat LGALS3BP protein Rat
GM-Tg-mg-IO086-Ag-1/ GM-Tg-mg-IO086-Ag-2 Mouse LGALS3BP protein Mouse
GM-Tg-cynog-IO086-Ag-1/ GM-Tg-cynog-IO086-Ag-2 Cynomolgus/Rhesus macaque LGALS3BP protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IO086-Ag-1/ GM-Tg-felg-IO086-Ag-2 Feline LGALS3BP protein Feline
GM-Tg-cang-IO086-Ag-1/ GM-Tg-cang-IO086-Ag-2 Canine LGALS3BP protein Canine
GM-Tg-bovg-IO086-Ag-1/ GM-Tg-bovg-IO086-Ag-2 Bovine LGALS3BP protein Bovine
GM-Tg-equg-IO086-Ag-1/ GM-Tg-equg-IO086-Ag-2 Equine LGALS3BP protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IO086-Ag-1/ GM-Tg-hg-IO086-Ag-2; GM-Tg-rg-IO086-Ag-1/ GM-Tg-rg-IO086-Ag-2;
GM-Tg-mg-IO086-Ag-1/ GM-Tg-mg-IO086-Ag-2; GM-Tg-cynog-IO086-Ag-1/ GM-Tg-cynog-IO086-Ag-2;
GM-Tg-felg-IO086-Ag-1/ GM-Tg-felg-IO086-Ag-2; GM-Tg-cang-IO086-Ag-1/ GM-Tg-cang-IO086-Ag-2;
GM-Tg-bovg-IO086-Ag-1/ GM-Tg-bovg-IO086-Ag-2; GM-Tg-equg-IO086-Ag-1/ GM-Tg-equg-IO086-Ag-2
Products Name LGALS3BP protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name LGALS3BP
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LGALS3BP protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.